

Bac Viet Le

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/37312/publications.pdf>

Version: 2024-02-01

11
papers

221
citations

1307594

7
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

368
citing authors

#	ARTICLE	IF	CITATIONS
1	4-1BBL“containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells. <i>Blood Advances</i> , 2022, 6, 1879-1894.	5.2	13
2	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Cancer Research</i> , 2021, 81, 5089-5101.	0.9	25
3	TGF β 2R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. <i>Cell Reports</i> , 2020, 33, 108221.	6.4	18
4	<i>TET2</i> and <i>DNMT3A</i> Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors. <i>Blood</i> , 2020, 136, 4-4.	1.4	1
5	PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions. <i>Leukemia and Lymphoma</i> , 2019, 60, 262-264.	1.3	9
6	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1098-1101.	1.3	12
7	Tyrosine kinase inhibitor“induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. <i>Blood</i> , 2018, 132, 67-77.	1.4	54
8	PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions. <i>Blood</i> , 2018, 132, 3000-3000.	1.4	0
9	Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. <i>Blood</i> , 2017, 130, 2848-2859.	1.4	64
10	Whole-exome sequencing identifies two novel missense mutations (p.L111P and p.R3048C) of RYR3 in a Vietnamese patient with autism spectrum disorders. <i>Genes and Genomics</i> , 2017, 39, 301-306.	1.4	2
11	MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs. <i>Blood Advances</i> , 2017, 1, 1467-1472.	5.2	23